Medical research

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 5, 2024
SAN, VUS, Genotype, Cancer, P572, MSH2, FRCPA, Research, OTC, City, FACMG, Hereditary nonpolyposis colorectal cancer, Medical research, MLH1, PMS2, P22, Disclosure, Arrhythmia, Cardiomyopathy, CGC, RNA, Classification, Infant, Phenotype, American College, Landscape, ACMG, Patient, Genetic testing, Gene, TTN, MMR, Science, Variant, Medical genetics, Laboratory, DNA, Partnership

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.

Key Points: 
  • SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16.
  • The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.
  • "The ACMG Annual Clinical Genetics Meeting is an incredible opportunity for our researchers and collaborators to highlight ongoing scientific advancements to support genetics-informed patient care," said W. Michael Korn, M.D., chief medical officer at Invitae.
  • Invitae plans to present posters (P164 and P073) about Lynch syndrome and VUS in mismatch repair (MMR) genes and multiplex assays of variant effects (MAVEs).

Stowers Institute Scientific Director Kausik Si receives coveted award from the Chan Zuckerberg Initiative

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Alzheimer's disease, Thought, Medical research, Neurodegenerative disease, Amyloid, Protein engineering, University, CZI, Memory, Research

KANSAS CITY, Mo., Feb. 21, 2024 /PRNewswire/ -- The Chan Zuckerberg Initiative (CZI) has announced the awardees of their second cycle of Collaborative Pairs Pilot Project Awards, part of the CZI Neurodegeneration Challenge Network (NDCN).

Key Points: 
  • Scientific Director Kausik Si, Ph.D., from the Stowers Institute for Medical Research will receive an award for the project titled, "Tuning memory by altering amyloids," which will be conducted alongside Investigator Lukasz Joachimiak, Ph.D., from the University of Texas Southwestern.
  • The Collaborative Pairs Pilot Project Awards were launched in 2018 to investigate neurodegenerative disease biology by aligning two scientists with diverse expertise.
  • Following the success of the first cycle, the NDCN expanded the research scope beyond neurodegenerative disease, seeking proposals covering broader neuroscience biology.
  • "The award from CZI to Kausik and his collaborator is a nod to the Stowers Institute's focus on spurring discovery and contributing scientific insight into some of the most difficult problems in the life sciences," said Stowers Institute President and Chief Scientific Officer Alejandro Sánchez Alvarado, Ph.D.

An awkward family reunion: Sea monsters are our cousins

Retrieved on: 
Wednesday, February 21, 2024
Blood pressure, Bangladesh Technical Education Board, Research, NIH, Animal, Medical research, Cell, Vertebrate, Mouth, Skeleton, Brainstem, Gene, Code, Nature Communications, Heart, Nightmare, DSM-IV codes, Human, Mouse, Jaw, Brain, Livestock

KANSAS CITY, Mo., Feb. 21, 2024 /PRNewswire/ -- The sea lamprey, a 500-million-year-old animal with a sharp-toothed suction cup for a mouth, is the thing of nightmares. A new study from the Stowers Institute for Medical Research discovered that the hindbrain—the part of the brain controlling vital functions like blood pressure and heart rate—of both sea lampreys and humans is built using an extraordinarily similar molecular and genetic toolkit.

Key Points: 
  • The team unexpectedly uncovered that a crucial molecular cue is very broadly required during vertebrate hindbrain development.
  • Because most vertebrates, including humans, have jaws, this striking difference in sea lampreys makes them valuable models for understanding the evolution of vertebrate traits.
  • Surprisingly, they found that the sea lamprey core hindbrain circuit is also initiated by retinoic acid, providing evidence that these sea monsters and humans are much more closely related than anticipated.
  • "People thought that because sea lampreys lack a jaw, their hindbrain was not formed like other vertebrates," said Krumlauf.

Smart Immune appoints key new members to its Board of Directors

Retrieved on: 
Friday, February 16, 2024
Transfer, Research, Infection, Growth, National Cancer Institute, Immunology, Treatment, Gesellschaft mit beschränkter Haftung, Therapy, Chemical industry in India, Development, Immune system, Roche, Amgen, Dow Chemical Company, Novartis, Farmitalia, Dow, Lazard, XPath, Medical research, Spark Therapeutics, ADC, Patient, Sanofi

Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.

Key Points: 
  • Markus Goebel, Grégoire Cayatte, Federico Mingozzi and Pablo Silveri will join existing directors, Dominique Costantini and Fouzia Laghrissi-Thode, to accelerate and support the growth of Smart Immune.
  • Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are delighted and proud to welcome such distinguished experts to the Board, led by Markus Goebel as our new Chairman.
  • We are grateful to our outgoing Chairman for his 5-year commitment and support to Smart Immune.”
    Markus Goebel, CEO and Founder of M&G Advisors and Chairman of Smart Immune’s Board of Directors, said: “I am thrilled to join and lead the Board of Smart Immune.
  • He is on the Boards of Halozyme, ADC Therapeutics and Aprea Therapeutics and now an Observer on the Board of Directors at Smart Immune.

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

Retrieved on: 
Monday, February 12, 2024
Cornell University, Acquisition, SAN, Sunovion, Merck, Research, Pharmacia & Upjohn, MD, Drug development, Growth, Research and development, University, Ōtsuka, Therapy, Advanz Pharma, Psychiatry, Development, Cell, Medical research, Pharmaceutical industry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.

Key Points: 
  • Dr. Corrigan brings over three decades of life sciences leadership experience to Silver Creek.
  • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.
  • "We are pleased to welcome Dr. Corrigan to lead Silver Creek through its next phase of growth," said Tim Throsby, Silver Creek's Chairman of the Board.
  • "The elegance and innovation behind Silver Creek's Smart Growth Factor™ platform is very compelling, and the pre-clinical data around scp776 is equally impressive.

Juntendo University Broadens the Scope of Mitochondrial Disease Testing

Retrieved on: 
Monday, February 12, 2024
Mitochondrial disease, Pediatrics, Medical research, Juntendo University, Clinical Laboratory, Mitochondrion, Cardiomyopathy, Hearing loss, RNA, Adolescence, Adenosine, Genetic testing, ATP, Disease, Insurance, Kidney, Diagnosis, Development, Research, DNA, Seizure, Pharmaceutical industry

TOKYO, Feb. 12, 2024 /PRNewswire/ -- Mitochondrial disease occurs when malfunctioning mitochondria cannot sustain the production of adenosine triphosphate (ATP)—the energy currency of life—in the inner mitochondrial membrane. The loss of this vital molecule has far-reaching consequences that affect various organ systems and can cause psychiatric symptoms, cardiomyopathy, seizures, kidney and liver dysfunction, and hearing loss.

Key Points: 
  • The Intractable Disease Research Center at Juntendo University will conduct broader analyses of mitochondrial genetic data to confirm genetic diagnosis.
  • Unfortunately, mitochondrial disease is the most common congenital metabolic condition, with one case detected for every 5000 live births.
  • In terms of testing, Juntendo University screens many babies diagnosed with mitochondrial disease each year.
  • In this regard, Prof. Murayama's team commenced mitochondrial disease outpatient care at Juntendo Medical Center's Pediatric and Adolescent Department in July 2023.

INTEGRATED ONCOLOGY NETWORK and cCARE WELCOME HEMATOLOGY ONCOLOGIST DR. PHILIP MARJON TO THEIR MEDICAL TEAM

Retrieved on: 
Thursday, February 8, 2024
Roger Williams Medical Center, Lankenau Medical Center, University, ION, Internal medicine, Medical director, Hematology, Medical research, Patient, Department of Biochemistry, Research, Knowledge, Nursing

NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team. 

Key Points: 
  • NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team.
  • We are excited to expand our team of expert medical professionals and enhance oncology care and support to our patients.
  • Philip Marjon, M.D., M.S., is a board-certified Hematologist and Medical Oncologist, having earned his medical degree from the University of New Mexico School of Medicine.
  • Dr. Marjon began his medical career as part of a research team with the University of New Mexico's Department of Biochemistry.

Feinstein Institutes research shows that psychiatric disorders are linked to dementia not through genetics, but alcohol use as shared cause

Retrieved on: 
Tuesday, February 6, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Multimedia, Memory, DSM-IV codes, Public, Language, UK Biobank, Medical research, Credit, Risk, Molecular medicine, Pharmaceutical industry

While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.

Key Points: 
  • While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.
  • “This research has helped us to recognize that alcohol use disorder greatly increases the chances of both psychiatric disorders and subsequent dementia.
  • This paves the way for future research to better inform interventions and care.”
    The study investigated the relationship between psychiatric disorders and known genetic risks of dementia.
  • The researchers conclude that shared risk factors may account for a large part of the association between psychiatric disorders and dementia, like alcohol use disorder that is a shared risk of both PDPD and dementia.

Pixelgen Technologies and Australian Biosearch Announce Distribution Agreement

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Neoplasm, Knowledge, Immunotherapy, MPX, Research, Membrane, Therapy, 3D, Proteome, Medical research, Protein, Disease, Drug development, Health, Hematology, Cancer, Translation

STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies® announced today a non-exclusive agreement with leading distributor Australian Biosearch. The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets. 

Key Points: 
  • STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies ® announced today a non-exclusive agreement with leading distributor Australian Biosearch .
  • The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets.
  • "The Australasian biotech market is rapidly growing, and this agreement will help ensure our products reach this important region as we expand globally."
  • Earlier this month, Pixelgen announced a distribution agreement for Japan and launched a sales team in the U.S. with a new global sales position in Boston.

Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

Retrieved on: 
Thursday, February 1, 2024
University, Research, Medical research, MD, Therapy, Gastroenterology, FDA, Habilitation, GPCR, Biotechnology, Drug discovery, Genentech, Drug development, Royal Free Hospital, Doctor of Philosophy, Medicine

Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.

Key Points: 
  • Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.
  • Eva-Lotta Allan, Chair of the Board of Directors commented: "It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion.
  • Dr Arndt Schottelius, incoming CEO said: "Maxion's truly revolutionary technology has the unique opportunity to deliver first-in-class and best-in-class protein therapeutics to treat ion channel and GPCR-driven diseases.
  • I am delighted to join Maxion Therapeutics at such an exciting time in the Company's development.